Skip to main content
. Author manuscript; available in PMC: 2018 Oct 2.
Published in final edited form as: Urol Oncol. 2017 May 8;36(10):459–468. doi: 10.1016/j.urolonc.2017.04.007

Fig. 2.

Fig. 2

PD-L1 can be expressed on both APCs and tumor cells. PD-L1 binds to PD-1 on the T-cell surface, leading to coinhibition of T-cell activity. The PD-1/PD-L1 pathway can be blocked with anti-PD-1/PD-L1 antibodies, leading to immune-mediated tumor destruction. (Color version of the figure available online.)